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ABSTRACT
We report a 19-year-old woman with
thrombosis of a prosthetic mitral valve that
was most likely due to a short dip in
anticoagulation in the days preceding the event.
Interestingly, at presentation the patient was
super-therapeutic, most likely a result of
hepatic congestion as the heart began to fail,
creating an illusion of thrombosis despite
adequate anticoagulation.
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INTRODUCTION
Metallic prosthetic valves are associated with an increased
risk of thrombosis and subsequent embolism.  The morbidity
and mortality associated with prosthetic valve thrombosis
(PVT) is substantial.  This risk is significantly greater with
valves in the mitral position, probably owing to lower
velocities of blood flow.  Meticulous anticoagulation with
warfarin reduces this risk considerably to approximately
0.2 per patient-year.(1) Most cases of PVT reported in the
literature are associated with consistently inadequate
anticoagulation.  However, there is no data on the dangers
of transient lapses in the level of anticoagulation.  We report
on a case of PVT occurring three months after implantation
with super-therapeutic anticoagulation at presentation, but
a short “dip” in levels in the days preceding the event.
CASE REPORT
A 19-year-old woman underwent mitral valve replacement
with a CarboMedics™ bileaflet mechanical valve for mitral
regurgitation three months prior to admission.  Her
postoperative course was unremarkable and international
normalised ratio (INR) at discharge was 3.2.  15 days prior
to admission, her INR decreased to 1.9, following which
the dose of warfarin was increased.  Five days prior to
admission, she developed progressively worsening
dyspnoea.  Physical examination revealed her to be afebrile
and in florid pulmonary oedema.  The prosthetic mitral
valve sounds were considerably muffled.  White blood cell
counts and subsequent blood cultures were unremarkable.
Transthoracic echocardiography revealed a transmitral
gradient of 28 mmHg with trivial mitral regurgitation.
Fig. 1 Fluoroscopic image of mitral valve shows immobile and
restricted leaflets.
Fig. 2 Photograph shows the excised mitral valve laden with
thrombus.
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A transoesophageal echocardiogram (TEE) confirmed the
above findings and suggested that the posterior mitral valve
disc was immobile.  No vegetations were seen.  At
fluoroscopy, the anterior disc was noted to have limited
excursion and the posterior disc was immobile (Fig. 1).
One day prior to admission, the patient’s INR was 4.6. The
patient underwent emergency replacement of her mitral
valve, this time with a bioprosthesis.  Perioperatively, the
valve was laden with thrombus with severe restriction of
both discs (Fig. 2). She has remained well since.
DISCUSSION
Thrombosis is an uncommon yet serious complication after
valve replacement with a mechanical prosthesis. The clinical
presentation can range from subtle embolic events to florid
pulmonary oedema and cardiogenic shock.  PVT should
be suspected with any deterioration in clinical status or
with thromboembolic complications. TEE and fluoroscopy
can reliably evaluate leaflet mobility and help in diagnosis
as well as follow-up of response to treatment.(2) Therapy
includes infusion of a thrombolytic agent for 27–72 hours,
with or without heparin, and aspirin(3) or surgery.(4)  Long-
term anticoagulation is recommended in all patients to
prevent PVT.  The American Heart Association and the
American College of Cardiology advocates an INR of
2.5–3.0 for bileaflet mechanical valves in the mitral
position.(5)
The majority of patients with PVT that have been
reported in the literature were attributed to inadequate
anticoagulation.  A more difficult question to answer is
whether the duration of subtherapeutic anticoagualation
that can lead to thrombosis is a continuous variable or has
a critical “cut-off” value.  In our patient, the relatively
suboptimal anticoagulation 15 days prior to admission
(INR 1.9) may have resulted in a nidus of thrombus forming
on the valve, eventually culminating in valve thrombosis.
The super-therapeutic levels of anticoagulation observed
at presentation may simply have been a consequence of
hepatic congestion secondary to a failing heart, providing
the illusion that this patient developed PVT despite being
well-anticoagulated.  Although not formally worked up,
there was no prior history of any hypercoagulable state.
It is unclear why our patient’s anticoagulation levels dropped
initially.  As far as we can ascertain, there were no interacting
drugs in her history nor was there an obvious dietary cause.
In conclusion, PVT can occur as a consequence of
transient dips in anticoagulation level. This case highlights
the dangers of failing to maintain adequate anticoagulation
in patients with metallic prosthetic valves, even for relatively
short durations. This is particularly true for developing
countries where rheumatic valvular heart disease is very
common and meticulous anticoagulation is logistically
difficult.
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